• Codexis Reports First Quarter 2021 Financial Results

    Source: Nasdaq GlobeNewswire / 06 May 2021 16:05:01   America/New_York

    Total Revenue up 23% and Product Revenue Doubles Year over Year

    REDWOOD CITY, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced financial results for the first quarter ended March 31, 2021 and provided a business update.

    “Codexis’ growth drivers are continuing to accelerate, and we began 2021 with strong momentum, especially in higher margin product sales within our Performance Enzymes segment,” said John Nicols, Codexis President and CEO. “Our Life Science Tools business continues to grow rapidly, with initial sales of our Codex® HiCap RNA polymerase, dozens of potential customer trials of our Codex® HiFi DNA polymerase, and excellent traction with new customer partnered Life Science Tools R&D programs. We continue to diversify our Sustainable Manufacturing business, with a more profitable mix of pharmaceutical products, and a growing presence in the faster-to-market food and industrial space. Our high-value Biotherapeutics pipeline is advancing across multiple programs, and we are on track to move our second asset into clinical studies later this year. Leveraging the power of our CodeEvolver® platform, Codexis is engineering enzymes that are enabling and delivering the promise of synthetic biology to improve the health of people and the planet.”

    Key Performance Indicators

    • Product revenues increased 101% to $10.2 million in Q1, driven by enzymes used to manufacture branded pharmaceutical products.
    • Product gross margin climbed to 59% in the first quarter of 2021, driven by a shift in the sales mix to higher margin products.
    • In the first quarter, Codexis had 15 customers who contributed over $100,000 in revenue and five customers who contributed over $1 million in revenue.
    • In the Life Science Tools market, Codexis recorded several initial orders of its Codex® HiCap RNA polymerase, which is also under testing by multiple mRNA manufacturers. Codex® HiFi DNA polymerase is being trialed by dozens of potential customers for use with current and future next gen sequencing kits. The first quarter of 2021 was Codexis’ strongest ever for new Life Science Tools customer-partnered R&D programs.
    • In the novel Biotherapeutics market, Codexis’ pipeline includes 12 programs. The Company has completed the necessary toxicology and GMP manufacturing for the first clinical study of CDX-7108, partnered with Nestlé Health Sciences for an undisclosed GI disorder, and Codexis continues to expect that the IND will be filed in the third quarter of 2021.

    First Quarter 2021 Financial Highlights

    • Total revenues for the first quarter 2021 were $18.0 million, an increase of 23% from $14.7 million in the first quarter 2020. On a segment basis, $14.2 million in revenue was from the Performance Enzymes segment and $3.8 million was from Novel Biotherapeutics. Product revenues for the first quarter 2021 were $10.2 million compared to $5.1 million in first quarter 2020; the increase was the result of higher sales of branded pharmaceutical products. R&D revenues were $7.8 million compared to $9.6 million last year; the decrease was primarily driven by lower revenue from Novartis.
    • Product gross margin for the first quarter 2021 was 59% compared to 50% in the first quarter 2020. The increase was driven by increased sales of higher margin products.
    • R&D expenses for the first quarter 2021 were $11.6 million compared to $11.0 million in the first quarter 2020. The increase was driven by higher compensation expenses, cost of lab supplies and depreciation, partially offset by lower preclinical development and regulatory expenses.
    • Selling, General & Administrative expenses for the first quarter 2021 were $11.4 million, compared to $9.0 million in the first quarter 2020. The increase was the result of higher expenses for legal fees and compensation, offset by lower travel and allocation expenses.
    • The net loss for the first quarter 2021 was $9.1 million, or $0.14 per share, compared to $7.7 million, or $0.13 per share, for the first quarter 2020. As of March 31, 2021, the Company had $139.7 million in cash and cash equivalents.

    Guidance

    Codexis reiterates its previously issued financial guidance for 2021, as follows:

    • Total revenues are expected to be in the range of $82 million to $85 million
    • Product revenues are expected to be in the range of $36 million to $39 million
    • Gross margin on product revenue is expected to be 54% to 58%

    Conference Call and Webcast

    Codexis will hold a conference call and webcast today beginning at 4:30 p.m. ET. A live webcast and slide presentation to accompany the conference call will be available on the Investor section of Company website. The conference call dial-in numbers are 877-705-2976 for domestic callers and 201-689-8798 for international callers, and the passcode is 13718548.

    A recording of the call will be available for 48 hours beginning approximately two hours after the completion of the call by dialing 877-660-6853 for domestic callers or 201-612-7415 for international callers. Please use the passcode 13716352 to access the recording. A webcast replay will be available on the Investors section of www.codexis.com for 30 days, beginning approximately two hours after the completion of the call.

    About Codexis

    Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® platform to discover and develop novel, high performance enzymes and novel biotherapeutics. Codexis enzymes have applications in the sustainable manufacturing of pharmaceuticals, food, and industrial products; in the creation of the next generation of life science tools; and as gene therapy and biologic therapeutics. The Company’s unique performance enzymes drive improvements such as: reduced energy usage, waste generation and capital requirements; higher yields; higher fidelity diagnostics; and more efficacious therapeutics. Codexis enzymes enable the promise of synthetic biology to improve the health of people and the planet. For more information, visit www.codexis.com.

    Forward-Looking Statements

    To the extent that statements contained in this press release are not descriptions of historical facts regarding Codexis, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve substantial risks and uncertainties that could cause Codexis’ future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, its guidance on 2021 total revenue, product revenue and gross margin on product revenue; its expectations regarding strong growth across multiple dimensions; anticipated future expansion of its high-value Biotherapeutics pipeline; and the expected initiation of the first clinical study of CDX-7108. Codexis undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Codexis’ business in general, please refer to Codexis’ prospectus supplement to be filed with the SEC, including the documents incorporated by reference therein, which include Codexis’ Annual Report on Form 10-K filed with the SEC on March 1, 2021 and Codexis’ other periodic reports filed with the SEC.

    Investor Relations Contact:
    Argot Partners
    Stephanie Marks/Carrie McKim
    (212) 600-1902
    Codexis@argotpartners.com


    Codexis, Inc.
    Condensed Consolidated Statements of Operations
    (Unaudited)
    (In Thousands, Except Per Share Amounts)

     Three Months Ended March 31,
     2021 2020
    Revenues:   
    Product revenue$10,226   $5,100  
    Research and development revenue7,806   9,570  
    Total revenues18,032   14,670  
    Costs and operating expenses:   
    Cost of product revenue4,218   2,541  
    Research and development11,571   10,967  
    Selling, general and administrative11,398   8,989  
    Total costs and operating expenses27,187   22,497  
    Loss from operations(9,155)  (7,827) 
    Interest income177   266  
    Other expenses, net(88)  (86) 
    Loss before income taxes(9,066)  (7,647) 
    Provision for income taxes2   5  
    Net loss$(9,068)  $(7,652) 
        
    Net loss per share, basic and diluted$(0.14)  $(0.13) 
        
    Weighted average common stock shares used in computing net loss per share, basic and diluted64,290   58,888  


    Codexis, Inc.
    Condensed Consolidated Balance Sheets
    (Unaudited)
    (In Thousands)

     March 31, 2021 December 31, 2020
    Assets   
    Current assets:   
    Cash and cash equivalents$139,748   $149,117  
    Restricted cash, current594   638  
    Investment in non-marketable debt security1,067   1,000  
    Financial assets:   
    Accounts receivable11,368   13,894  
    Contract assets5,143   4,526  
    Unbilled receivables11,298   10,942  
    Total financial assets27,809   29,362  
    Less: allowances(74)  (74) 
    Total financial assets, net27,735   29,288  
    Inventories1,029   964  
    Prepaid expenses and other current assets3,390   3,416  
    Total current assets173,563   184,423  
    Restricted cash1,519   1,062  
    Investment in non-marketable equity securities2,350   1,450  
    Right-of-use assets - Operating leases, net20,758   21,382  
    Right-of-use assets - Finance leases, net94   119  
    Property and equipment, net10,396   9,675  
    Goodwill3,241   3,241  
    Other non-current assets249   294  
    Total assets$212,170   $221,646  
        
    Liabilities and Stockholders' Equity   
    Current liabilities:   
    Accounts payable$3,569   $2,970  
    Accrued compensation4,953   7,288  
    Other accrued liabilities9,516   10,272  
    Current portion of lease obligations - Operating leases2,618   2,627  
    Deferred revenue1,897   1,824  
    Total current liabilities22,553   24,981  
    Deferred revenue, net of current portion2,900   2,967  
    Long-term lease obligations - Operating leases21,701   22,324  
    Other long-term liabilities1,277   1,271  
    Total liabilities48,431   51,543  
        
    Stockholders' equity:   
    Common stock6   6  
    Additional paid-in capital539,220   536,516  
    Accumulated deficit(375,487)  (366,419) 
    Total stockholders' equity163,739   170,103  
    Total liabilities and stockholders' equity$212,170   $221,646  
        


    Codexis, Inc.
    Segmented Information
    (Unaudited)
    (In Thousands)

     Three months ended March 31, 2021 Three months ended March 31, 2020
     Performance Enzymes Novel Biotherapeutics Total Performance Enzymes Novel Biotherapeutics Total
    Revenues:           
    Product revenue$10,226  $—   $10,226   $5,100  $—   $5,100  
    Research and development revenue4,003  3,803   7,806   5,774  3,796   9,570  
    Total revenues14,229  3,803   18,032   10,874  3,796   14,670  
    Costs and operating expenses:           
    Cost of product revenue4,218  —   4,218   2,541  —   2,541  
    Research and development (1)6,444  4,605   11,049   5,696  4,925   10,621  
    Selling, general and administrative(1)2,818  600   3,418   2,345  591   2,936  
    Total segment costs and operating expenses13,480  5,205   18,685   10,582  5,516   16,098  
    Income (loss) from operations$749  $(1,402)  (653)  $292  $(1,720)  (1,428) 
    Corporate costs (2)    (7,728)      (5,727) 
    Unallocated depreciation and amortization    (685)      (492) 
    Loss before income taxes    $(9,066)      $(7,647) 
                

    (1) Research and development expenses and selling, general and administrative expenses exclude depreciation and amortization of finance leases.
    (2) Corporate costs include unallocated selling, general and administrative expense, interest income, and other income and expenses.

     


    Primary Logo

Share on,